01 Industry overview
The neuromodulation industry at a glance
The global neuromodulation devices market is estimated at $7.0 billion in 2026, with North America holding 43.4% of 2025 revenue and adaptive, closed-loop stimulation driving product development.
- $7.0B[5]
- 2026 market estimate
- 10.4%[5]
- 2026–2033 forecast CAGR
- 43.4%[5]
- North America share, 2025
- 42.8%[5]
- Spinal cord stimulators share, 2025
- Market size
- The global neuromodulation devices market was valued at $6.4 billion in 2025 and is estimated at $7.0 billion in 2026. A separate market estimate places the broader neuromodulation market at $7.22 billion in 2026.[5][7]
- Forecast & CAGR
- Grand View Research forecasts the neuromodulation devices market to reach $13.9 billion by 2033, representing a 10.4% CAGR from 2026 to 2033. Mordor Intelligence forecasts the broader market to reach $10.93 billion by 2031 at an 8.65% CAGR from 2026 to 2031.[5][7]
- Market share & regions
- North America accounted for 43.4% of global neuromodulation devices revenue in 2025, making it the largest regional market. The United States accounted for 36.0% of global neuromodulation devices revenue in 2025 in one country-level estimate.[5][12]
- Segmentation
- Spinal cord stimulators were the largest product segment, representing 42.8% of market revenue in 2025. The market is also segmented into deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, peripheral nerve stimulation and non-invasive modalities such as transcranial magnetic stimulation.[5][7]
- Key players & concentration
- The principal commercial competitors include Medtronic, Boston Scientific, Abbott, Nevro, LivaNova and BIOTRONIK. Mordor Intelligence characterizes market concentration as medium; no reliable source reviewed provided a directly comparable combined share for the leading companies.[7][5]
- Pricing
- A 2025 International Pain and Spine Intervention Society summary reported average insurer costs of $55,635 for spinal cord stimulation, including the device, medical and hospital costs for the initial procedure and re-interventions. An Ontario evidence review estimated approximately $34,660 in total five-year costs for 10-kHz spinal cord stimulation, including device costs.[13][14]
- Trends, drivers & challenges
- Growth is being supported by neurological disease prevalence, demand for minimally invasive treatment and advances in sensing and closed-loop stimulation. Boston Scientific estimated the 2025 served market at approximately $2.5 billion for spinal cord stimulation and $1.0 billion for deep brain stimulation, while competition from non-invasive tools remains a challenge.[5][15][16]
- Consumer behavior & competition
- Demand is concentrated in chronic pain and movement-disorder treatment, with providers increasingly adopting systems that personalize stimulation. The competitive landscape includes established implantable-device manufacturers and newer peripheral-nerve and wearable-stimulation companies; no reliable source reviewed provided a comparable global patient or consumer adoption rate.[5][7]
- M&A
- M&A activity has expanded neuromodulation portfolios: Globus Medical agreed to acquire Nevro for approximately $250 million in 2025, Boston Scientific agreed to acquire Nalu Medical for approximately $533 million in 2025, and Boston Scientific completed the Nalu acquisition in January 2026 for approximately $523 million net of cash acquired.[17][18]
- Regulation
- The U.S. FDA approved an adaptive deep brain stimulation programming feature for Medtronic’s Activa, Percept and SenSight systems on February 20, 2025. The approval covers bilateral stimulation of the globus pallidus or subthalamic nucleus for specified patients with levodopa-responsive Parkinson’s disease.[10]
- Latest news
- In 2026, Boston Scientific completed its acquisition of Nalu Medical for approximately $523 million net of cash acquired, integrating the business into its Neuromodulation division. Medtronic also completed its acquisition of SPR Therapeutics in July 2026, adding temporary peripheral nerve stimulation technology for chronic and acute pain.[17][19]
02 Ranking
Top 10 Companies in the Neuromodulation Industry
The leading companies in the neuromodulation industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Boston Scientific stands out for neuromodulation devices covering movement disorders and chronic pain because it had an 18% operating margin in 2025, while BrainsWay focuses on Deep TMS for psychiatric indications since it commercializes systems cleared for depression, OCD, and smoking cessation.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in deep brain stimulation
Boston Scientific
US
Ranked #1 · 9.4 · Deep brain stimulation
Why we picked it: Its neuromodulation business develops devices for movement disorders and chronic pain with an 18% operating margin in 2025.
Leader in noninvasive brain stimulation
BrainsWay
IL
Ranked #2 · 8.9 · Noninvasive brain stimulation
Why we picked it: It commercializes Deep TMS systems cleared for depression, OCD, smoking cessation and related indications.
Leader in sacral neuromodulation
Medtronic
IE
Ranked #3 · 8.6 · Sacral neuromodulation
Why we picked it: It reports a dedicated Neuromodulation operating unit spanning pain, brain and pelvic-health therapies.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Boston Scientific Deep brain stimulation · US | 9.4 | 9.9 | 9.9 | 9.5 | 8.8 | |
Company snapshot · Boston Scientific · Data as of November 20, 2026 Boston Scientific's Neuromodulation business develops devices for movement disorders and chronic pain.[15]
| |||||||
| 2 | BrainsWay Noninvasive brain stimulation · IL | 8.9 | 8.0 | 9.5 | 9.9 | 9.4 | |
Company snapshot · BrainsWay · Data as of November 20, 2026 BrainsWay commercializes Deep TMS systems cleared for depression, OCD, smoking cessation and related indications.[20]
| |||||||
| 3 | Medtronic Sacral neuromodulation · IE | 8.6 | 9.8 | 7.8 | 7.7 | 7.3 | |
Company snapshot · Medtronic · Data as of November 20, 2026 Medtronic reports a dedicated Neuromodulation operating unit spanning pain, brain and pelvic-health therapies.[21]
| |||||||
| 4 | SetPoint Medical Vagus-nerve stimulation · US | 8.3 | 7.0 | 8.3 | 8.9 | 9.9 | |
Company snapshot · SetPoint Medical · Data as of November 20, 2026 SetPoint is launching a neuroimmune modulation therapy for rheumatoid arthritis in the United States.[22]
| |||||||
| 5 | LivaNova Vagus-nerve stimulation · GB | 8.2 | 8.7 | 7.8 | 7.2 | 8.6 | |
Company snapshot · LivaNova · Data as of November 20, 2026 LivaNova reported $592.8 million of 2025 Neuromodulation revenue across all regions.[23]
| |||||||
| 6 | Saluda Medical Closed-loop spinal cord stimulation · AU | 8.1 | 7.0 | 8.3 | 8.5 | 9.4 | |
Company snapshot · Saluda Medical · Data as of November 20, 2026 Saluda Medical develops closed-loop spinal cord stimulation using evoked compound action potentials.[24]
| |||||||
| 7 | NeuroPace Responsive brain stimulation for epilepsy · US | 8.0 | 7.7 | 8.3 | 8.5 | 8.9 | |
Company snapshot · NeuroPace · Data as of November 20, 2026 NeuroPace sells the RNS System, an implantable responsive neurostimulator for epilepsy.[17]
| |||||||
| 8 | Inspire Medical Systems Implantable upper-airway stimulation for OSA · US | 8.0 | 8.6 | 7.0 | 7.4 | 8.6 | |
Company snapshot · Inspire Medical Systems · Data as of November 20, 2026 Inspire sells an implantable neurostimulation system for obstructive sleep apnea.[25]
| |||||||
| 9 | Mainstay Medical Implantable restorative neurostimulation for back pain · IE | 7.9 | 7.7 | 8.3 | 7.7 | 7.4 | |
Company snapshot · Mainstay Medical · Data as of November 20, 2026 Mainstay Medical markets ReActiv8, an implantable restorative neurostimulation system for chronic low-back pain.[26]
| |||||||
| 10 | electroCore Noninvasive vagus-nerve stimulation · US | 7.6 | 7.5 | 8.3 | 7.0 | 7.0 | |
Company snapshot · electroCore · Data as of November 20, 2026 electroCore sells gammaCore and other noninvasive vagus-nerve stimulation products.[17]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Margot Villeneuve. (2026, February 13). Top 10 companies in the neuromodulation industry. In Neuromodulation Industry Statistics. Gitnux. https://gitnux.org/neuromodulation-industry-statistics/#top-companies
Revenue of the largest neuromodulation companies
Medtronic leads with $36.4B in annual revenue (group level, converted to USD).
03 Trends & forecasts
Top 10 Neuromodulation Industry Trends & Forecasts 2027
What is changing in the neuromodulation industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Market growth remains above ten percent
High confidenceThe global neuromodulation devices market was estimated at $7.0 billion in 2026, up from $6.4 billion in 2025, and is forecast to reach $13.9 billion by 2033 at a 10.4% CAGR. North America represented 43.4% of 2025 revenue.[5]
Forecast 2027: The market should approach approximately $7.7 billion in 2027 if the published 2026–2033 growth path holds. Growth will remain broad-based but concentrated in pain, movement disorders and newer peripheral-nerve applications.
02Chronic pain drives implant demand
High confidenceSpinal cord stimulators accounted for 42.8% of 2025 neuromodulation-device revenue, while Boston Scientific estimated the 2025 served SCS market at approximately $2.5 billion. Chronic pain therefore remains the largest commercial demand pool.[5][15]
Forecast 2027: In 2027, SCS should remain the largest product category, but growth is likely to shift toward differentiated waveforms, peripheral nerve stimulation and solutions for diabetic and nonsurgical pain.
03Adaptive stimulation moves into routine development
High confidenceThe FDA approved Medtronic's adaptive deep brain stimulation programming feature on February 20, 2025, for specified Parkinson's disease patients using Activa, Percept and SenSight systems. The feature uses device sensing to adjust stimulation programming.[10]
Forecast 2027: By 2027, adaptive and sensing-enabled systems should become a standard product-development requirement in DBS and an increasingly important differentiator in SCS. Commercial adoption will remain limited by clinical workflow, programming evidence and reimbursement.
04Deep brain stimulation expands selectively
Medium confidenceBoston Scientific estimated the 2025 served DBS market at approximately $1.0 billion, with movement disorders as the principal served indication. Grand View Research identifies Parkinson's disease as the leading neuromodulation-device application.[15][5]
Forecast 2027: DBS revenue should grow faster than the overall market in 2027 if adaptive programming and rechargeable sensing systems gain adoption. Expansion into additional neurological and psychiatric indications will remain evidence- and regulation-dependent.
05Peripheral nerve stimulation gains strategic weight
High confidenceMedtronic completed its acquisition of SPR Therapeutics on July 16, 2026, for $650 million, adding temporary percutaneous peripheral nerve stimulation for chronic and acute pain. Boston Scientific also completed its acquisition of Nalu Medical, which develops peripheral nerve stimulation for severe chronic peripheral-nerve pain.[19][18]
Forecast 2027: Peripheral nerve stimulation should be one of the fastest-expanding segments in 2027 as large manufacturers broaden beyond traditional SCS. Competition will focus on shorter procedures, temporary implants and targeted treatment of focal pain.
06Large companies consolidate pain portfolios
High confidenceGlobus Medical completed its Nevro acquisition in April 2025 for approximately $250 million. Boston Scientific completed the Nalu acquisition, and Medtronic completed the SPR acquisition in 2026, demonstrating continued portfolio consolidation.[27][18][19]
Forecast 2027: Further acquisitions or partnerships are likely in 2027, especially involving peripheral stimulation, software, sensing and non-opioid pain therapies. The market should become more concentrated even though several specialist competitors remain active.
07Asia Pacific outpaces mature regions
Medium confidenceGrand View Research identifies Asia Pacific as the fastest-growing regional market, with an 11.46% forecast CAGR from 2026 to 2033, compared with a 43.4% North American revenue share in 2025.[5]
Forecast 2027: Asia Pacific should gain incremental global share in 2027, supported by rising neurological disease burden, expanding specialist capacity and broader access to implantable therapies. North America will remain the largest revenue market.
08U.S. remains the commercial anchor
High confidenceThe U.S. neuromodulation devices market generated $2.521 billion in revenue in 2025 and is estimated at $2.756 billion in 2026. Its forecast CAGR from 2026 to 2033 is 9.8%.[5]
Forecast 2027: U.S. revenue should exceed $3.0 billion in 2027 if the published growth trajectory continues. Adoption will remain strongest in hospitals, ambulatory surgery centers and specialist pain and movement-disorder practices.
09Procedure economics remain a barrier
High confidenceA 2025 International Pain and Spine Intervention Society analysis reported average insurer costs of $55,635 for SCS, including the initial procedure and re-interventions. An Ontario Health assessment estimated five-year costs of approximately $34,660 for a 10-kHz wireless SCS system.[13][28]
Forecast 2027: In 2027, manufacturers and providers will emphasize lower total episode costs, fewer re-interventions and outpatient implantation. Cost-effectiveness evidence will increasingly influence payer coverage and purchasing decisions.
10Re-intervention pressure accelerates reliability innovation
High confidenceThe 2025 IPSIS analysis found that 23.0% of patients required surgical re-intervention within 36 months after definitive SCS implantation. The reported median time to first re-intervention was 16.8 months.[13]
Forecast 2027: By 2027, competitive claims will increasingly center on durability, lead stability, battery life, explant reduction and remote programming. Products that reduce revision procedures should gain preference even where their upfront prices are higher.
04 Statistics
Technology
The technology section quantifies patent pipelines and issued holdings, including Nevro’s 115 pending applications as of December 31, 2024 and 294 issued patents globally held by Nevro.
R&D, patents and design rights in the neuromodulation industry
- 115 patent applications were pending globally for Nevro as of December 31, 2024, including 49 U.S. applications and 66 PCT or foreign applications.[1]
- 779 neurotechnology patents, including neuromodulation and modulation-related inventions, were identified in a 2025 landscape using the study’s patent-search methodology; 39 patents raised ethical concerns.[2]
- 294 issued patents were held globally by Nevro as of December 31, 2024, covering spinal-cord-stimulation systems and other neuromodulation technologies.[1]
05 Statistics
Market Intelligence
The market-intelligence section ties multiple market definitions to sizing and forecasting, including $7.0 billion for neuromodulation devices in 2026 and a $13.9 billion 2033 forecast.
Market size, volume and shipments in the neuromodulation industry
- USD 7.11 billion was the estimated global neuromodulation market size in 2025, covering internal and external neuromodulation technologies, applications, end users and regions.[3]
- USD 7.2 billion was the estimated global neuromodulation market size in 2024, covering neuromodulation devices and related technologies as defined by Market Glass.[4]
- USD 6.4 billion was the estimated global neuromodulation-devices market size in 2025, covering spinal cord, deep brain and sacral nerve stimulators and related devices.[5]
- USD 6.81 billion was the estimated global neuromodulation market size in 2025, based on MarketsandMarkets' category definition covering technology, stimulation type, application and end user.[6]
Forecast growth and shipments in the neuromodulation industry
- The global neuromodulation market is forecast to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, implying 9.4% CAGR for 2025–2030.[6]
- The global neuromodulation-devices market is forecast to reach USD 13.9 billion by 2033 from USD 7.0 billion in 2026, implying 10.4% CAGR for 2026–2033.[5]
- The global neuromodulation market is forecast to reach USD 10.93 billion by 2031 from USD 7.22 billion in 2026, implying 8.65% CAGR for 2026–2031.[7]
06 Statistics
Strategy & Growth
The strategy-and-growth section reports transaction volume and disclosed value in the broader segment, and it documents neuromodulation portfolio consolidation via announced and completed acquisitions.
M&A and consolidation in the neuromodulation industry
- 548 transactions, including 98 M&A deals, were recorded in the broader cardiovascular, neuromodulation and robotics medtech segment in 2024; the source includes deals with undisclosed values.[8]
- $38 billion in disclosed transaction value, including $31.5 billion of M&A value, was recorded in the broader cardiovascular, neuromodulation and robotics medtech segment in 2024.[8]
- $3.7 billion was the 2024 acquisition value for Axonics, a sacral-neuromodulation-device company, acquired by Boston Scientific.[9]
07 Statistics
Product & Standards
The product-and-standards section lists FDA-recognized standards, including ISO 14708-3:2017 and IEC 60601-2-10 Edition 2.2 with FDA recognition entered in May 2025.
Standards, grades and specs for neuromodulation
- ISO 14708-3:2017 is FDA-recognized as a complete standard for active implantable medical devices intended for electrical stimulation of the central or peripheral nervous system; U.S. recognition entered June 7, 2018.[10]
- IEC 60601-2-10 Edition 2.2, dated January 2023, received complete FDA recognition on May 26, 2025 for basic safety and essential performance of nerve and muscle stimulators.[10]
- ANSI/AAMI NS4:2013(R)2017 is FDA-recognized as a complete standard for transcutaneous electrical nerve stimulators, with U.S. recognition entered January 14, 2019.[10]
08 Statistics
Customers & Channel
The customers-and-channel section assigns external-neuromodulation device demand by setting, with hospitals at 42.1% of the 2025 global external-neuromodulation market value.
Demand by end use for neuromodulation
- 42.1% of the 2025 global external-neuromodulation device market was attributed to hospitals, measured by market value; the category includes TENS, TMS, VNS and other external devices.[11]
- 31.7% of the 2025 global external-neuromodulation device market was attributed to clinics, measured by market value; the category includes TENS, TMS, VNS and other external devices.[11]
- US hospitals and ambulatory surgery centers represented $1,992.4 million of neuromodulation-device demand in 2023, measured by market value; the report segments neuromodulation devices by end-user setting.[6]
09 Statistics
Regulation & Risk
The regulation-and-risk section tracks FDA-listed recall activity for totally implanted spinal-cord stimulators under product code LGW, down from 5 in 2024 to 3 in 2026.
Recalls and safety notices for neuromodulation
- 14 FDA-classified recalls were posted for totally implanted spinal-cord stimulators under product code LGW in the United States during 2024–2026, down from 5 in 2024 to 3 in 2026; the classification covers a core neuromodulation-device segment.[10]
- 12 of 25 FDA-listed recalls for totally implanted spinal-cord stimulators under product code LGW were posted by Medtronic Neuromodulation, compared with 7 by Boston Scientific Neuromodulation and 3 by Abbott Medical, through November 16, 2026.[10]
- 134 Nalu neurostimulation-system units were in commerce in a U.S. nationwide Class II recall posted October 29, 2026, after a firmware issue could make the therapy disc non-functional.[10]
Key questions about the Neuromodulation Industry
What is the size of the global neuromodulation devices market in 2026?
How fast is the neuromodulation devices market forecast to grow after 2026?
Which companies lead the neuromodulation industry?
What technology shift is most associated with new product development in neuromodulation devices?
How is the market distributed by region and by product segment?
What reimbursement economics are reported for spinal cord stimulation in the U.S.?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Margot Villeneuve. (2026, February 13). Neuromodulation Industry Statistics. Gitnux. https://gitnux.org/neuromodulation-industry-statistics
Margot Villeneuve. "Neuromodulation Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neuromodulation-industry-statistics.
Margot Villeneuve. 2026. "Neuromodulation Industry Statistics." Gitnux. https://gitnux.org/neuromodulation-industry-statistics.
Sources & references
28 sources cited across this report
docs.publicnow.com
nature.com
valuemarketresearch.com
marketresearch.com
grandviewresearch.com
marketsandmarkets.com
mordorintelligence.com
outcomecapital.com
iqvia.com
accessdata.fda.gov
dataintelo.com
emergenresearch.com
- cdn.ymaws.com
hqontario.ca
investors.bostonscientific.com
rothschildandco.com
sec.gov
news.bostonscientific.com
news.medtronic.com
investors.brainsway.com
medtronic.com
- setpointmedical.com
livanova.gcs-web.com
neuromodulation.com
s204.q4cdn.com
doi.org
investors.globusmedical.com
ontariohealth.ca
